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Abstract  
 
Although functional magnetic resonance imaging (fMRI) has gained increasing importance in 
investigating neural substrates of anxiety disorders, less is known about the stress eliciting 
properties of the scanner environment itself. The aim of the study was to investigate 
feasibility, self-reported distress and anxiety management strategies during an fMRI 
experiment in a comprehensive sample of patients with panic disorder and agoraphobia 
(PD/AG). Within the national research network PANIC-NET, n=89 patients and n=90 
controls participated in a multicenter fMRI study. Subjects completed a retrospective 
questionnaire on self-reported distress, including a habituation profile and exploratory 
questions about helpful strategies. Drop-out rates and fMRI quality parameters were 
employed as markers of study feasibility. Different anxiety measures were used to identify 
patients particularly vulnerable to increased scanner anxiety and impaired data quality. Three 
(3.5%) patients terminated the session prematurely. While drop-out rates were comparable for 
patients and controls, data quality was moderately impaired in patients. Distress was 
significantly elevated in patients compared to controls; claustrophobic anxiety was 
furthermore associated with pronounced distress and lower fMRI data quality in patients. 
Patients reported helpful strategies, including motivational factors and cognitive coping 
strategies. The feasibility of large-scale fMRI studies on PD/AG patients could be proved. 
Study designs should nevertheless acknowledge that the MRI setting may enhance stress 
reactions. Future studies are needed to investigate the relationship between self-reported 
distress and fMRI data in patient groups that are subject to neuroimaging research.   
 
Keywords: fMRI; Neuroimaging; Anxiety disorders; Panic disorder; Agoraphobia; Stress   
 
 
 
1. Introduction  
 
Although functional magnetic resonance imaging (fMRI) has gained increasing importance in 
investigating neural substrates of anxiety disorders (Paulus, 2008), less is known about the 
stress eliciting properties of the scanner environment itself. Reports about routine care 
patients indicate that an MRI examination can produce subjective distress (Dantendorfer et 
al., 1997; Flaherty and Hoskinson, 1989; Kilborn and Labbe, 1990; Mackenzie et al., 1995; 
McIsaac et al., 1998) or trigger long-term claustrophobia (Fishbain et al., 1988; Kilborn and 
Labbe, 1990) and panic attacks (Spiegelhalder et al., 2009) in subjects with no previous 
psychiatric history. Pre-existing claustrophobia may moreover predict distress and panic 
symptoms in the scanner (McIsaac et al., 1998). Adverse reactions not only constitute a 
significant problem for patients: they can affect the performance of (f)MRI studies by 
increasing the number of declined appointments, premature terminations of scans, or impair 
data quality (Dantendorfer et al., 1997).  
 
Scanner distress ranges from moderate apprehension (approx. 30%), to severe panic and 
claustrophobia experienced by 5–10% of routine care patients (Melendez and McCrank, 
1993). Among anxiety patients, those suffering from panic disorder and agoraphobia (PD/AG) 
are particularly vulnerable to the stress eliciting properties of the MRI, which is a highly 
agoraphobic/claustrophobic stimulus. Comprehensive assessments of scanner distress in PD 
are still lacking, but Bystritsky et al. (2001) found elevated panic symptoms in patients 
compared to controls. Maddock et al. (2003) stated that four out of six patients reported 
feeling anxious throughout the scan. Pillay et al. (2006) observed that although all eight 
patients were able to complete the scan, they showed initial signs of hesitation. Interpretation 
of these observations is however limited by the small number of patients and lack of 
quantitative assessment tools.  
 
The aim of the present study was to investigate scanner-related effects on self-reported 
distress and data quality in a multicenter fMRI study on n=89 PD/AG patients, addressing the 
following research questions:  
 
1) Are large-scale fMRI studies in PD/AG patients (dropout-rates, data quality) feasible?  
2) Do patients and controls differ in their amount of distress before, during and after the 
session?  
3) Can we identify vulnerable patients using different measures of anxiety?  
4) Management strategies: what can we do to make patients feel more comfortable?  
 
 
2. Experimental procedures  
 
2.1. Multicenter study PANIC NET  
 
The fMRI study was embedded within a national research network (PANIC-NET; Arolt et al., 
2009; Gloster et al., 2009) that is characterized by a multilevel and multicenter research 
structure, encompassing a randomized controlled clinical trial on cognitive behavioural 
therapy (CBT) and experimental add-on studies on fear circuit mechanisms in PD/AG. Eight 
centers participated in the clinical trial (Aachen, Berlin-Adlershof, Berlin-Charité, Bremen, 
Dresden, Greifswald, Münster, and Würzburg) treating n= 369 patients who met DSM-IV 
criteria for PD/AG. Four centers (Aachen, Berlin-Charité, Dresden, and Münster) also 
participated in the fMRI study which had been approved by all responsible ethics committees 
of the participating centers (research cluster P7: “Neuronal plasticity following cognitive-
behavioral therapy in patients with panic disorder: a multicenter 3-Tesla study using fMRI”).  
 
2.2. Subjects  
 
Eighty-nine PD/AG patients and 90 healthy controls participated in the fMRI study; n=87 
patients also participated in the clinical trial. Patient inclusion criteria encompassed a primary 
diagnosis of PD/AG according to the criteria of DSM-IVTR as assessed by the Composite 
International Diagnostic Interview (CAPI-WHO-CIDI; DIAX-CIDI version; Wittchen and 
Pfister, 1997), a score ≥18 at the Hamilton-Anxiety-Scale (SIGH-A; Shear et al., 2001), a 
score ≥4 at the Clinical Global Impressions Scale (CGI; Guy, 1976), age between 18 and 60 
years. Exclusion criteria encompassed psychotic or bipolar I disorders, current threshold 
alcohol or substance dependence, current suicidal tendency, borderline personality disorder, 
organic mental disorders, concurrent psychotherapeutic/ psychopharmacological treatments, 
severe cardiovascular, renal, and neurological diseases, colour blindness and any MRI-related 
exclusion criteria. Exclusion criteria were either assessed by entry into the clinical trial or 
prior to participation in the fMRI study. The control group was matched for gender, 
education, age, and handedness. Subjects were excluded in case of any current or lifetime 
diagnosis of any mental disorder (except misuse of alcohol and nicotine dependence), 
neurological disorders, central-nervous medication within the last four weeks, colour 
blindness, and MRI-related contraindications.  
 
2.3. Procedure  
 
Following inclusion into the clinical trial, patients were asked for participation in the fMRI 
study. Controls were recruited via advertisements and flyers. Subjects were scheduled an 
appointment (baseline assessment) at the scanner to obtain informed consent and to offer a 
try-out (e.g. lying in the tomograph). The fMRI session consisted of three functional runs and 
a structural scan (overall duration: 60 min), after which patients completed a questionnaire on 
subjective experiences during the fMRI session. All subjects were invited for a second fMRI 
assessment (post assessment) after completion of the therapy; only data from the baseline 
assessment are reported here. All subjects received 25€ for each assessment.  
 
2.4. Measurements  
 
2.4.1. Anxiety measures and scanner-related distress  
 
Within two weeks of the fMRI appointment, a psychometric characterization of patients was 
obtained by the clinical trial (see Gloster et al., 2009). The following measures were selected 
for present analyses: SIGH-A, Panic and Agoraphobia Scale (PAS; Bandelow, 1999), Anxiety 
Sensitivity Index (ASI; Reiss et al., 1986), Claustrophobia Questionnaire (CLQ; Radomsky et 
al., 2001), and Beck Depression Inventory (BDI II; Beck et al., 1996).  
 
The fMRI questionnaire was completed directly after the session, assessing a) degree of 
exhaustion caused by the scanner session, b) duration of anxiety, c) overall maximum anxiety, 
and d) a habituation profile on anticipatory anxiety before scanning (pre-start anxiety), at 
beginning (start-scan anxiety) and after completion (post-scan anxiety). All ratings were 
scored on a 9-point Likert scale. Patients were furthermore asked what had helped them to 
participate in the fMRI study. Questionnaire data are available for n=76 patients and n=55 
controls.  
 
2.4.2. fMRI paradigms and quality parameters  
 
The paradigms addressed different functions of the fear circuit (see Arolt et al., 2009), 
encompassing fear conditioning, interoceptive processing and symptom provocation using 
agoraphobic visual stimuli. MRI images were acquired on 3-Tesla MRI scanners. Standard 
head coils and headphones were applied. Visual stimuli were presented using video goggles 
(Aachen, Dresden: VisuaStim Digital, Northridge, California) or beamer projection (Münster, 
Berlin). Functional measurements were obtained using T2* weighted gradient echo planar 
images (EPI) sequences.  
 
The quality of fMRI time-series is crucial for within- and between-site reliability. 
Realignment parameters (SPM5; http://www.fil.ion.ucl.ac.uk/spm/) were used to quantify the 
amount of motion artifacts. We furthermore used the automated quality assurance routine 
introduced by Stocker et al. (2005), which gives one dispersion measure per volume 
(averaged across voxels) expressed as percent signal change relative to the mean of the time-
series (e.g., percent signal fluctuation). The measure is based on temporal fluctuations within 
a time-series which is expressed by the difference of each scan (e.g. time-point) to the mean 
image of the series. Higher average differences indicate relatively higher temporal variation in 
the signal. The dispersion measure is based on realigned data (Stocker et al., 2005). 
Realignment parameters (averaging x, y, and z values) and dispersion measures were 
calculated for each paradigm in order to analyze the time course of data quality within the 
session. In addition, mean translation and rotation indicators and dispersion measures were 
averaged to characterize overall quality of fMRI data in patients and controls.  
 
2.5. Data analysis  
 
Sample characteristics and drop-out rates were tested using t-tests for independent samples, 
chi2 or Fisher's exact tests. Since fMRI quality parameters were skewed distributed, Friedman 
tests and Mann–Whitney-U-tests were used to test for changes within the session from the 
first to the third paradigm (separately for patients and controls) and for group differences 
(patients (stratified for CLQ values) vs. controls) in overall data quality. Gender effects on 
fMRI quality parameters and subjective distress were analyzed using Mann–Whitney-U-tests 
and t-tests, respectively. Differences in self-reported distress between patients and controls 
were analyzed using t-tests (degree of exhaustion, duration of anxiety, and maximum 
anxiety), and a two-way analysis of variance (ANOVA; within-subjects-factor “time course”, 
between-subjects factor “group”). Associations between anxiety measures and self-reported 
distress were evaluated using Pearson's correlations. When testing differences in distress 
between high vs. low claustrophobic patients and controls the BDI II score was entered as a 
covariate into the ANCOVA model in order to control for unspecific depressive symptoms. 
Greenhouse–Geisser adjustments were applied when appropriate. Effect sizes (Cohen, 1983) 
were computed for all analyses on hypotheses (Cohen's d≥0.20, r≥0.10 and f2≥0.10: small 
effects; d≥0.50, r≥0.30 and f2≥0.25: medium effects; d≥0.80, r≥0.50 and f2≥0.40: large 
effects). A level of α<0.05 indicated statistical significance. All analyses were carried out 
using PASW 17.0.  
 
 
 
 
3. Results  
 
3.1. Sample characteristics, dropout-rates and data quality  
 
Sample characteristics are displayed in Table 1, separately for the entire sample and the 
sample for which the fMRI questionnaire was available. The majority of patients (n=61; 
68.54%) and controls (n=61; 67.78%) were female (chi2 (1)=0.012, p=0.913);mean age (SD) 
averaged at 36.48 years (11.31) for patients and 35.56 years (10.87) for controls (t 
(176)=0.56, p=0.580). Patients' clinical characteristics indicated moderate to severe severity 
for general and symptom-specific anxiety as measured by SIGH-A, PAS, ASI, and CLQ. In 
order to assure that the reduced sample for which questionnaire data were available was 
representative for the entire sample, differences in demographic, clinical, and data quality 
parameters were tested. Both patient and control samples were comparable in all variables 
(patients sample 1 vs. 2: gender: chi2 (1)=0.24, p=0.62; age: t (163)=0.44, p=0.66; SIGH-A: t 
(161) =−0.42, p=0.67; PAS: t (161)=−0.69, p=0.489; ASI: t (161)= −0.51, p=0.613; CLQ: t 
(161)=−0.79, p=0.433; BDI II: t (161)= −0.48, p=0.634; dispersion measure: Z=−0.89, 
p=0.373; translation: Z=−0.38, p=0.707; rotation: Z=−0.14, p=0.890; controls sample 1 vs. 2: 
gender: chi2 (1)=0.08, p=0.773; age: t (143)=0.53, p=0.597; BDI II: t(138)=0.68, p=0.495; 
dispersion measure: Z=- 0.06, p=0.950; translation: Z=-0.48, p=0.629; rotation: Z=-0.34, 
p=0.734).  
 
While all controls completed the fMRI session, three out of 89 patients (3.5%) terminated 
prematurely due to heightened anxiety. Drop-out rates were comparable between groups 
(Fisher's exact test: p=0.121).  
 
Overall mean quality parameters were significantly impaired in patients, showing higher 
mean percent signal fluctuations, translation and rotation parameters (dispersion measure: Z= 
−3.10, p= 0.002, d=0.47; translation: Z=−2.60, p= 0.009, d=0.29; rotation: Z=−2.64, p=0.008, 
d=0.34; Fig. 1). We observed no differences between female and male subjects in neither 
group regarding mean data quality (dispersion measure: controls: Z=−0.54, p= 0.589, d=0.10; 
patients: Z=−1.34, p=0.179, d=0.33; translation: controls: Z=−0.44, p=0.663, d=0.04; 
patients: Z=−0.79, p=0.430, d=0.27; rotation: controls: Z=−0.44, p=0.663, d=0.05; patients: 
Z=−0.45, p=0.654, d=0.17).  
 
The dispersion measure was comparable for all paradigms in the course of the fMRI session 
(dispersion measure: controls: chi2 (2)=0.43, p=0.808, f2<0.01; patients: chi2 (2)=0.38, 
p=0.828, f2 =0.15). We observed a significant time effect for translation and rotation 
parameters with decreasing values over time in controls, but only a non-significant trend in 
patients (translation: controls: chi2 (2) = 12.56, p= 0.002, f2=0.10; patients: chi2 (2 )=4.97, 
p=0.084, f2=0.18; rotation: controls: chi2 (2)=15.53, p<0.001, f2=0.19; patients: chi2 (2)=5.37, 
p=0.068, f2=0.10).  
 
3.2. Scanner-related distress: differences between patients and controls  
 
Patients were stronger distressed, reporting significantly higher maximum anxiety, exhaustion 
and anxiety persistence (maximum anxiety: t (129)=8.97, p<0.0001, d=1.87; exhaustion: t 
(128)= 9.92, p<0.0001, d=1.59; duration: t (129)=10.58, p<0.0001, d=1.76). The ANOVA on 
the habituation profile yielded a significant main effect of group (patients>controls; F (1, 
129)=150.06, p<0.0001, f2=1.08), of time course (start-scan>pre-scan>postscan; F (2, 
227)=30.56, p<0.0001, f2=0.49) and for the interaction group*time course (F (2, 227)=5.85, 
p=0.005, f2=0.21). Patients exhibited higher distress than controls at all three time points (pre-
scan, start-scan, post-scan: patients>controls; p<0.0001). Moreover, patients showed 
significant changes over time, with distress peaking at the start and significant reductions of 
both anticipatory and scanner-related anxiety towards the end of the session (patients: start-
scan>pre-scan>post-scan, p<0.001). In contrast, pre- and post-scan anxiety did not differ in 
controls (controls: start-scan>pre- scan, p<0.05; start-scan>post-scan, p<0.01; Fig. 2). No 
gender effects were observed for subjective distress in patients or controls (controls: 
maximum anxiety: t (52)=1.14, p=0.258, d=0.33; exhaustion: t (52)=0.24, p=0.809, d=0.07; 
duration: t (52)=0.55, p=0.586, d=0.16; pre-scan anxiety: t (52)=0.14, p=0.892, d=0.04; start-
scan anxiety: t (52)=0.629, p=0.53, d=0.18; post-scan anxiety: t (52)=−0.49, p=0.627, d=0.14; 
patients: maximum anxiety: t (74)=−1.14, p=0.269, d=0.27; exhaustion: t (74)=−1.05, 
p=0.277, d=0.26; duration: t (74)= −0.26, p=0.533, d=0.15; pre-scan anxiety: t (74)=−1.52, 
p=0.134, d=0.36; start-scan anxiety: t (74)=−0.34, p=0.733, d=0.08; post-scan anxiety: t 
(74)=−1.06, p=0.295, d=0.24).  
 
3.3. Identification of vulnerable patients using anxiety measures  
 
Claustrophobic anxiety was closest related to subjective distress (Table 2), displaying 
moderate, but significant correlations. Using a median split procedure on the patient group 
according to CLQ values (Table 3), comparison of low and high CLQ patients showed not 
only elevated anxiety, but also stronger depressive symptoms in high CLQ patients, so that 
the BDI II score was used as a covariate in subsequent analyses.  
 
When analyzing differences in subjective distress between high and low claustrophobic 
patients and healthy controls a main effect for exhaustion, duration and maximum anxiety was 
observed (exhaustion: F (2, 124)=38.89, p<0.0001, f2=0.79; duration: F (2, 123) =37.79, 
p<0.0001, f2 =0.79; maximum anxiety: F (2, 124)=48.18, p<0.0001, f2 =0.88). As expected, 
controls exhibited lower anxiety ratings than both patient groups; high CLQ patients reported 
significantly stronger exhaustion than low CLQ patients (exhaustion: high CLQ>low 
CLQ>controls, p<0.01; duration: high CLQ>low CLQ, p=0.08; patients>controls, p<0.0001; 
maximum anxiety: high CLQ>low CLQ, p= 0.065, patients>controls, p<0.0001). During the 
course of the session differential changes in habituation profiles were observed as indicated 
by a significant interaction effect of group and time course (main effect group: F (2, 
124)=67.74, p<0.0001, f2=1.05, high CLQ>low CLQ>controls, p<0.01; main effect time 
course: F (2, 248)=19.91, p<0.0001, f2=0.40, start-scan>pre-scan>post scan, p<0.0001; 
interaction effect group* time course: F (4, 248) =4.42, p= 0.003, f2 = 0.26). Controls reported 
reductions in anxiety from start-scan to post scan only (p<0.05), while in low CLQ patients 
anxiety significantly rose immediately during the start of the session (start-scan>pre-scan, 
post-scan, p<0.001). High CLQ patients did not only have a higher level of general anxiety as 
indicated by the significant main effect of group, but also showed reduced post-scan anxiety 
levels when compared to pre-scan levels (start-scan>pre-scan>post-scan, p<0.0001; see Fig. 
2).  
 
High vs. low CLQ subjects also differed in data quality. High, but not low claustrophobic 
patients showed significantly lower data quality parameters compared to controls, thus 
limiting this effect to the presence of claustrophobic anxiety to this subgroup (high CLQ vs. 
controls: dispersion: Z = −3.17, p=0.002, d=0.67; translation: Z=−2.73, p=0.006, d=0.31; 
rotation: Z=−2.41, p=0.002, d=0.42; low CLQ vs. controls: dispersion: Z=−0.66, p=0.512, 
d=0.19; translation: Z=−0.31, p=0.761, d=0.05; rotation: Z=−0.81, p=0.421, d=0.09; high 
CLQ vs. low CLQ: dispersion: Z=−2.30, p=0.021, d=0.46; translation: Z=−2.04, p=0.042, 
d=0.40; rotation: Z=−1.28, p=0.20, d=0.35; see Fig. 1).  
 
Since other anxiety measures, among them anxiety sensitivity, were also related to self-
reported distress, the specificity of CLQ results was tested employing the ASI as alternative 
group divisor within the patient group. Analyses yielded no significant differences between 
high and low ASI patients (exhaustion: F (1, 72)=0.92, p=0.341, f2=0.12; duration: F (1, 
72)=1.29, p=0.259, f2=0.14; max. anxiety: F (1, 72)=3.07, p=0.084, f2=0.21; main effect of 
group: F (1, 72)=0.55, p=0.462, f2=0.09; main effect of time course: F (2, 124)=11.41, 
p<0.0001, f2=0.40; interaction effect group* time course: F (2, 124)=0.22, p=0.774, f2=0.06). 
Quality parameters were comparable as well (dispersion measure: Z=−0.38, p=0.70, d=0.06; 
translation: Z=−0.14, p=0.882, d=0.04; rotation: Z=−0.23, p=0.816, d=0.11).  
 
3.4. Anxiety management strategies  
 
Patients told us what had helped or motivated them to go (and remain) in the scanner. 
Answers were grouped into seven categories encompassing the following: information (“I was 
given sufficient information about the scanner and procedure”), experience/exposure (“I want 
to overcome my anxiety”), research (“I want to support research and help other patients”), 
company (“someone was there and held my hand”), equipment (“I could not see the scanner 
through the goggles”), try-out (“I could try-out the scanner before participating in the study”), 
and cognitive coping strategies (“I knew I could leave the scanner at any time”). Frequencies 
are displayed in Fig. 3.  
 
 
4. Discussion  
 
The present study is among the first to investigate anxiety-eliciting properties of the MRI 
scanner itself in a comprehensive sample of patients suffering from PD/AG. The feasibility of 
large-scale fMRI studies in this vulnerable patient group was tested using drop-out rates and 
fMRI quality control data as sensitive indicators. Self-reported distress in patients was 
assessed using a newly developed questionnaire. Special emphasis was laid upon identifying 
vulnerable patients by anxiety measures. Finally, we aimed to find out how we can make the 
fMRI session more comfortable for patients.  
 
Results showed that PD/AG patients had no significantly higher drop-out rates. We 
nevertheless observed significant impairments in data quality, indicating stronger movement 
artifacts in patients. In line with this, self-reported distress was markedly increased in patients. 
Higher distress was especially related to claustrophobic anxiety. CLQ, but not ASI scores 
differentiated between high and low distressed patients. Only high, but not low CLQ patients 
displayed significantly lower fMRI data quality compared to controls. Patients reported 
factors helping them to participate in the study, among them provision of information, 
willingness to self-exposure, interest in research, and cognitive coping strategies.  
 
By successfully scanning n=86 PD/AG patients, we were able to prove that comprehensive 
fMRI studies on PD/AG patients are feasible without significant increases in drop-out rates. 
Changes in movement parameters over time were observed in controls only, in line with the 
observation that nervousness (and accompanying movements) may be highest in the 
beginning of the session. In patients, however, data quality-measures did not change over 
time. Although mean data quality was lower in patients than controls, effect sizes were small. 
Subgroup analyses on claustrophobic anxiety moreover indicated, that this effect was 
restricted to high claustrophobic patients, while low claustrophobic patients were comparable 
to controls. Regarding realignment parameters, mean translation measures averaged at one 
mm which is fairly within limits of tolerable movements.  
 
Patients were markedly stressed by the scanner environment as indicated by large effect sizes 
for all group comparisons. We observed pronounced distress levels, being three to four times 
higher than in controls. Distress also increased in controls when starting the scanner session 
which is well in line with reports about routine care patients (Melendez and McCrank, 1993). 
All subjects reported reduced anxiety ratings post scanning, being indicative of a habituation 
process that appeared to take place in both patients and controls. Only patients, however, 
showed enhanced pre-scan compared to post-scan values, reflecting elevated anticipatory 
anxiety.  
 
Claustrophobic anxiety has been reported to predict self-reported distress towards the scanner 
environment (McGlynn et al., 2003; McIsaac et al., 1998). Although previous studies were 
conducted on routine care patients or students, we could confirm the relevance of 
claustrophobic anxiety in this regard for PD/AG patients as well. From all anxiety measures, 
CLQ scores correlated highest with distress. In line with this, high CLQ, but not high ASI 
patients showed more self-reported distress and lower data quality, pointing towards a 
specificity of claustrophobic anxiety for scanner related distress. The prevalence of female 
patients was twice as high in the high CLQ group. This effect could be interpreted in terms of 
a higher symptom severity of PD/AG especially in female patients. Female and male subjects 
were however comparable regarding fMRI data quality and subjective distress. Findings on 
claustrophobic anxiety may indicate that especially those PD/AG patients are at risk for 
experiencing high levels of distress who have an agoraphobic focus on claustrophobic 
situations (and not, for example, being in a public, but spaced area or being left alone).  
 
Patients reported several helpful strategies in controlling their anxiety. This is in accordance 
with previous studies on management strategies for scanner-induced distress (Grey et al., 
2000) that employed measures of information delivery (e.g. booklets), counseling, cognitive 
distraction strategies or relaxation techniques. Since the MRI can act as a powerful anxiety 
trigger, first attempts using cognitive-behavioral interventions in overcoming scanner related 
resistance have been conducted (Klonoff et al., 1986). From a therapist's perspective, patients' 
cognitive avoidance and safety strategies should be eliminated during an exposure session in 
order to facilitate extinction learning. From a researcher's perspective, however, we would 
recommend to include as many safety signs into the scanner environment as possible, in order 
to help the patient to control his/her anxiety.  
 
Physiological processes such as respiration and heart rate may be influenced by different 
degrees of subjective distress during scanning. Variation of these parameters may account for 
physiological noise in BOLD data, which may increase error variance and affect the statistical 
power of fMRI analyses (Birn et al., 2006; Beall, 2010). Due to the absence of physiological 
coregistrations, we cannot determine if potential alterations in cardio-respiratory processes 
may have contributed to the higher percentage signal fluctuation seen in high claustrophobic 
patients.  
 
Scanner distress can furthermore increase neuroendocrine stress markers (Eatough et al., 
2009; Tessner et al., 2006). Cortical and subcortical structures that are involved in cognitive 
and affective processes, including prefrontal structures, hippocampi and amygdala, exert a 
high density of glucocorticoid-binding receptors (Reul and de Kloet, 1986). Depending on the 
amount of hormonal reactions, stress responses induced by the MRI setting could in some, but 
not all, subjects directly modulate neural activity (Muehlhan et al., 2010). As a consequence, 
interindividual variance in imaging data – either due to different levels of physiological noise 
or due to direct neurohormonal interactions – may be present. In clinical research, attention 
should therefore be drawn to the comparison of (distressed) patients and (relaxed) healthy 
controls. With regard to the interpretation of fMRI data it is especially important to carefully 
control potentially confounding variables, for example by including movement parameters in 
the fMRI design model on individual subject level and/or exclusion of outliers in the 
dispersion measure. To reduce the effect of global changes in BOLD response it is especially 
important to provide effective control conditions in an event related design, assuming that 
effects of distress are present in both, experimental and control conditions, and are not 
confounded with the experimental design. However, due to the possible increase of noise or 
ceiling effects (e.g. within the anxiety network) in the patient data there is a potentially 
reduced sensitivity, making it especially difficult to interpret an absence of activation in the 
patient group. Future studies are needed to evaluate the impact of these potentially 
confounding factors on functional activation patterns (Birn et al., 2009). An alternative 
approach might be to implement training activities that familiarize subjects with the scanner 
and thus reduce stress reactivity.  
 
Results should be interpreted within the methodological limits of the study. Being conducted 
as a multicenter trial, some heterogeneity regarding time/staff resources, possibilities of try-
outs and individual handling of patients has to be anticipated. When treating each patient 
individually in regard to his/her individual needs, standardization of patient interaction may 
instead be counterproductive. Moreover, different interaction styles may be more 
representative for MRI centers in general, enhancing external validity of results. All patients 
included in this study were referred to psychological treatment. This may have influenced 
motivation for participating in the fMRI study. Low drop-out rates and high compliance may 
not be representative for other fMRI studies on PD/AG patients. Subjective distress was 
measured by self-reports only, the study is lacking hormonal or autonomic measures. We can 
only speculate on the potential influence of self-reported distress on fMRI data via several 
neurohormonal axes. Although previous studies indicate hormonal responsiveness towards the 
scanner (Eatough et al., 2009; Tessner et al., 2006), it is yet unknown if results from healthy 
subjects can be translated to PD/AG patients, where alterations in HPA axis activity have 
been found (Petrowski et al., 2010). It would be a valuable task for future studies to 
investigate the influence of the MRI environment on hormonal or autonomic measures in 
these patients.  
 
In conclusion, the feasibility of large-scale fMRI studies on PD/AG patients that may be 
especially vulnerable to the stress eliciting properties of the MRI environment could be 
proved. Studies should stronger acknowledge psychological consequences of the MRI 
environment itself. Particular attention should be drawn to the adverse effects of the MRI 
setting that may enhance stress reactions. Future studies are clearly needed to investigate the 
relationship between self-reported distress and fMRI data in patient groups that are subject to 
neuroimaging research.  
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